Severe prolonged immunosuppression following fludarabine and rituximab combination therapy

Chemotherapy

Volumn 54, Issue 3, 2008, Pages 242-244

  Hudson, Emma ^a   Westmoreland, Diana ^b   Gorman, Christopher ^b   Poynton, Christopher H ^b   Lester, Jason F ^a   Maughan, Timothy S ^a  

^a VELINDRE CANCER CENTRE   (United Kingdom)

^b UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATOVAQUONE; CHLORAMBUCIL; CIDOFOVIR; CLADRIBINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; FLUDARABINE; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN; MITOXANTRONE; PREDNISOLONE; PURINE DERIVATIVE; RITUXIMAB; VALGANCICLOVIR; VINCRISTINE;

ANAMNESIS; BLOOD TOXICITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CYTOMEGALOVIRUS INFECTION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENCEPHALITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LETTER; LYMPHOMA; MONOTHERAPY; MOUTH ULCER; MULTIPLE CYCLE TREATMENT; MYCOSIS; NONHODGKIN LYMPHOMA; PANCYTOPENIA; PRIORITY JOURNAL; RETINITIS; SIDE EFFECT; T LYMPHOCYTE;

AGED; ANTIBODIES, MONOCLONAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNE TOLERANCE; LYMPHATIC DISEASES; MIDDLE AGED; VIDARABINE;

EID: 46649098041     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000140469     Document Type: Letter

References (13)

1. Cheson BD: Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol 1995;13:2431-2448.
2. Morrison VA: The infectious complications of chronic lymphocytic leukaemia. Semin Oncol 1998;25:98-106.
3. Doan AL, Doan A, Canpinar H, Duzguncinar O, Demirpence E: Effect of fludarabine on leukocyte functions. Chemotherapy 2004;50:283-288.
4. Morrison VA, Rai KR, Peterson BL, Kolitz JE, Elias L, Appelbaum FR, et al: Impact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011. J Clin Oncol 2001;19:3611-3621.
5. Hochster H, Weller E, Kuzel T, Frankel S, Horning S: Increased mortality associated with higher dose cyclophosphamide plus fludarabine (CF) in advanced stage indolent lymphoma patients treated on E1496, an Eastern Cooperative Oncology Group (ECOG) and CALGB study. Proc Am Soc Clin Oncol 2002;21:282a.
6. Robak T, Szmigielska-Kaplon A, Bloski JZ, Kasznicki M, Chojnowski K: Activity of cladribine combined with etoposide in heavily pretreated patients with indolent lymphoid malignancies. Chemotherapy 2005;51:247-251.
7. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a fourdose treatment program. J Clin Oncol 1998;16:2825-2833.
8. Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B: Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitises a B-cell lymphoma line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997;12:177-186.
9. Czuczman MS, Koryzna A, Mohr A, Stewart C: Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol 2005;23:694-704.
10. Savage DG, Cohen NS, Hesdorffer CS, Heitjan D, Oster MW, Garrett TJ, et al: Combined fludarabine and rituximab for low grade lymphoma and chronic lymphocytic leukaemia. Leuk Lymphoma 2003;44:477-481.
11. Byrd JC, Peterson BL, Morrison VA, Park K, Jacobson R, Hoke E, et al: Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukaemia: results from Cancer and Leukaemia Group B 9712. Blood 2003;101:6-14.
12. McLoughlin P, Hagemeister FB, Rodriguez MA, Sarris AH, Pate O, Younes A, et al: Safety of fludarabine, mitoxantrone and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma. Semin Oncol 2000;27:37-41.
13. Forstpointner R, Dreyling M, Repp R, Hermann S, Hanel A, Metzner B, et al: The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004;104:3064-3071.